Navigation Links
Big Arrow Group Expands Global Capabilities with Addition of Anne de Schweinitz

NEW YORK, Feb. 12 /PRNewswire/ -- Big Arrow Group, a New York-based full-service strategic consulting and communications firm, today announced that Anne de Schweinitz has joined the company.

As a member of Big Arrow's leadership team, Ms. de Schweinitz will be responsible for driving business growth by ensuring the success of current client programs and by expanding Big Arrow's offerings and expertise, especially in the area of global pharmaceutical and healthcare consulting.

Ms. de Schweinitz brings deep experience in healthcare marketing and communications to Big Arrow Group. She joins the firm following nearly 10 years at MS&L, a global communications agency within the Publicis Groupe of companies, where she served most recently as senior vice president and global account director for the agency's largest healthcare client, Eli Lilly and Company. In addition to overseeing teams in North American and Europe working in the areas of diabetes, cardiovascular disease, women's health and erectile dysfunction, Anne worked closely with Lilly's U.S. and global brand teams to help align and reposition the company's broad offering in diabetes.

"Success as a global account director for major companies and brands, especially in highly regulated industries, requires exceptional strategic insight and creative savvy. Anne has built an excellent reputation as a trusted advisor to her clients, helping them address their most critical business needs through highly differentiated and influential communications programs," said Mike Marino, president and founder of Big Arrow Group.

Prior to joining MS&L's New York office in 2006, Ms. de Schweinitz held positions in San Francisco and London, where she led the agency's global accounts for sanofi-aventis as well as programs on behalf of numerous pharmaceutical, biotech, medical device and healthcare delivery companies in a wide range of therapeutic areas.

Before joining MS&L, Ms. de Schweinitz work for the University of California, San Francisco, where she helped drive internal communications and supported public relations activities for corporate, clinical and research news. She is a Phi Beta Kappa graduate of Rutgers University and is active in a number of community and arts organizations in the New York area.

About Big Arrow Group

Big Arrow Group is a full-service strategic consulting and communications firm specializing in global brand development, marketing planning and integrated communications, new product development and market research. The firm has redefined communications deliverables through research and case-tested strategies to provide their clients with practical, easily activated strategies that build and accelerate brand momentum. Founded in 2004, Big Arrow Group is headquartered in New York City.

Big Arrow Group provides strategic planning and corporate brand development in technology, healthcare, pharmaceutical and business-to-business for a wide range of clients, including Biocodex, Genzyme Corporation, Northeast Utilities and Bayer Schering Pharma. To learn more about the Big Arrow Group, please visit

SOURCE Big Arrow Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
3. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
4. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
5. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
6. Arrow International Announces Annual Meeting Voting Results
7. Shareholder Class Action Filed Against Aetna Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System
9. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
10. Beactica Announces Drug Discovery Collaboration With Arrow Therapeutics
11. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, ... again for its stellar workplace culture with the company’s Cincinnati office being named ... Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Los Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... advanced da Vinci surgical robot is being more and more widely heralded as a ... robotic assisted da Vinci method has over traditional laparoscopic surgery is that it can ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology: